Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 69

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 69
---
 a result, a patent owner may have limited remedies in certain circumstances, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Further, the standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. As such, we do not know the degree of future protection that we will have on our technologies and product candidate. While we will endeavor to try to protect our technologies and product candidate with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive, and unpredictable. In addition, geopolitical actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any future licensors and the maintenance, enforcement, or defense of our issued patents or those of any future licensors. As a result, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected. Intellectual property rights do not necessarily address all potential threats to our competitive advantage. The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

| • |     | others may be able to make or use product candidates that are similar to ours, but that are not covered by the 
 claims of our patents or pending patent applications;                                                          |

| • |     | we or future collaborators might not have been the first to make the inventions covered by the pending patent 
 application that we own or have exclusively licensed;                                                         |

| • |     | we or future collaborators might not have been the first to file patent applications covering certain of our or 
 their inventions;                                                                                               |

| • |     | others may independently develop similar or alternative technologies or duplicate any of our technologies without 
 infringing or otherwise violating our intellectual property rights;                                               |

| • |     | it is possible that noncompliance with the USPTO and foreign governmental patent agencies’ requirements for                                                                                                                                        
 a number of procedural, documentary, fee payment, and other provisions during the patent process can result in abandonment